Elder Pharmaceuticals has entered into an alliance with Laboratorios Farmaceuticos Rovi (ROVI) of Spain to market advanced heparins (anti-thrombotics) in India for treatment and prevention of thrombo-embolic venous diseases like deep vein thrombosis and pulmonary embolism. According to an official release issued by Elder Pharmaceuticals to the BSE today, to begin with, the joint initiative shall see the introduction in India of the patented, US FDA approved product Bemiparin, a second-generation low molecular weight heparin (LMWH) for the prevention & treatment of thrombo-embolic venous diseases. In India, Bemiparin would be launched with the brand name of HIBOR shortly. The total anti-thrombotic market in India is Rs 130 crore with products mainly from the MNCs like Sanofi, Aventis, Knoll, Pharmacia, Novartis, etc. Elder hopes to garner between 8% and 10% market share in the first year of launch itself, the release said. "Anti-thrombotics constitute an important niche market for us and we wanted to bring the most effective product range in this category to India" Alok Saxena, international director, Elder Pharmaceuticals, said. Established in Spain in 1946, Laboratorios Farmaceuticos Rovi, S.A (ROVI) is a euro 100 million research-backed pharmaceutical firm selling its products in more than 20 countries. ROVI invests 18% of its turnover in R&D and also exports science & technology to over 30 countries. ROVI pursues two very specialized lines of research, concentrating its efforts on the prevention and treatment of venous thrombo-embolic disease and contrast agents for image diagnosis. Source: Business Standard March 14, 2007

<< Back